Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 2Phase NA 1Phase 3 1

Status

Unknown 2Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × EC regimen × Clear all
NCT05834582 2023-04-28

Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
60 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01210768 2021-11-23

A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients

TTY Biopharm

Phase 2 Unknown
254 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡